A qualitative study of ovarian cancer survivors' perceptions of endpoints and goals of care

被引:35
作者
Frey, Melissa K. [1 ]
Philips, Sarah R. [1 ]
Jeffries, Julia [2 ]
Herzberg, Andrea J. [3 ]
Harding-Peets, Gwen L. [3 ]
Gordon, Judith K. [3 ]
Bajada, Lorraine [3 ]
Ellis, Annie E. [3 ]
Blank, Stephanie V. [1 ]
机构
[1] NYU, Langone Med Ctr, New York, NY 10016 USA
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[3] SHARE, New York, NY USA
关键词
Cancer survivors; Ovarian cancer; Treatment endpoints; Goals of care; PATIENT-REPORTED OUTCOMES; ONCOLOGY; PREFERENCES; SYMPTOMS; MEDICINE; THERAPY; TRIAL;
D O I
10.1016/j.ygyno.2014.09.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives. A survey of the Ovarian Cancer National Alliance revealed a communication gap between physicians and survivors. This qualitative study explored the space between perceptions in hopes of better defining treatment endpoints meaningful to treating physicians and their patients. Methods. A focus group of ovarian cancer survivors (n = 22) was assembled via the survivor support network SHARE. A physician-guided session explored expectations of treatment, perceived outcomes, toxicity thresholds and decision making. The session was recorded, transcribed and coded. Common themes were identified and used to perform intra-case analysis by two independent reviewers. Results. The main themes identified were barriers to communication, importance of frequent communication between patient and physician regarding goals, and expectations of treatment changing with position along the treatment continuum. One hundred percent of participants identified communication with their physician as an essential element in determining treatment course. However, only 14% reported having a discussion about goals, values and perceptions with their physician preceding treatment decisions. Participants reported that the terms progression free and overall survival held minimal significance for them and instead they preferred an individualized approach to care focusing on quality of life. Many women underreported side effects with reasons ranging from fear of dose reductions and additional tests to forgetting about symptoms due to anxiety. Conclusions. An objective measure of treatment success meaningful to survivors, physicians and regulators is, at present, elusive and may not exist. Ideally, future trial design would place equal weight on quantitative and qualitative measures and include information about goals of treatment. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:261 / 265
页数:5
相关论文
共 23 条
[1]  
[Anonymous], 2002, N ENGL J MED, V346, P1061
[2]  
[Anonymous], DYN TOOLS MEAS HLTH
[3]   Bridging the gap: decision-making processes of women with breast cancer using complementary and alternative medicine (CAM) [J].
Balneaves, Lynda G. ;
Truant, Tracy L. O. ;
Kelly, Mary ;
Verhoef, Marja J. ;
Davison, B. Joyce .
SUPPORTIVE CARE IN CANCER, 2007, 15 (08) :973-983
[4]   Electronic Toxicity Monitoring and Patient-Reported Outcomes [J].
Basch, Ethan M. ;
Reeve, Bryce B. ;
Mitchell, Sandra A. ;
Clauser, Stephen B. ;
Minasian, Lori ;
Sit, Laura ;
Chilukuri, Ram ;
Baumgartner, Paul ;
Rogak, Lauren ;
Blauel, Emily ;
Abernethy, Amy P. ;
Bruner, Deborah .
CANCER JOURNAL, 2011, 17 (04) :231-234
[5]  
Berkowitz S., 1997, USER FRIENDLY HDB MI
[6]  
Bogdan R.C., 1997, Qualitative research for education: An introduction to theory and methods, V3rd
[7]   Trends in complementary/alternative medicine use by breast cancer survivors: Comparing survey data from 1998 and 2005 [J].
Boon H.S. ;
Olatunde F. ;
Zick S.M. .
BMC Women's Health, 7 (1)
[8]  
Cohen L, 2008, CURR CLIN ONCOL, P3, DOI 10.1007/978-1-59745-183-3_1
[9]   2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) [J].
du Bois, A ;
Quinn, M ;
Thigpen, T ;
Vermorken, J ;
Avall-Lundqvist, E ;
Bookman, M ;
Bowtell, D ;
Brady, M ;
Casado, A ;
Cervantes, A ;
Eisenhauer, E ;
Friedlaender, M ;
Fujiwara, K ;
Grenman, S ;
Guastalla, JP ;
Harper, P ;
Hogberg, T ;
Kaye, S ;
Kitchener, H ;
Kristensen, G ;
Mannel, R ;
Meier, W ;
Miller, B ;
Neijt, JP ;
Oza, A ;
Ozols, R ;
Parmar, M ;
Pecorelli, S ;
Pfisterer, J ;
Poveda, A ;
Provencher, D ;
Pujade-Lauraine, E ;
Randall, M ;
Rochon, J ;
Rustin, G ;
Sagae, S ;
Stehman, F ;
Stuart, G ;
Trimble, E ;
Vasey, P ;
Vergote, I ;
Verheijen, R ;
Wagner, U .
ANNALS OF ONCOLOGY, 2005, 16 :7-12
[10]   Therapy for Advanced Stage Cancer: What Do Patients Want and Expect? A Patient Advocate's Perspective [J].
Erwin, Robert L. .
ONCOLOGIST, 2010, 15 :11-12